Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 21, 2015, Pages 6742-6747

  Tsai, Shang Yi A ^a   Pokrass, Michael J ^a,b   Klauer, Neal R ^a,c   Nohara, Hiroshi ^a,d   Su, Tsung Ping ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d Komagino Hospital   (Japan)

Author keywords

Axon; cdk5; Myristic acid; p35; Sigma 1 receptor

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ACRIDINE ORANGE; CALCIMYCIN; CALPAIN; CALPAIN 2; CALPASTATIN; CYCLOHEXIMIDE; CYTOCHROME C; CYTOSKELETON PROTEIN; IMMUNOGLOBULIN; LACTACYSTIN; MESSENGER RNA; MYRISTIC ACID; PROTEIN N MYRISTOYLTRANSFERASE; PROTEIN P25; PROTEIN P35; SIGMA 1 OPIATE RECEPTOR; SMALL INTERFERING RNA; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TAU PROTEIN; CDK5R1 PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE 5; MAPT PROTEIN, MOUSE; PHOSPHOTRANSFERASE; PROTEASOME; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN SLICE; BRAIN SYNAPTOSOME; COMPARATIVE STUDY; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MYRISTYLATION; NERVE ELONGATION; NERVE ENDING; NERVE FIBER; NONHUMAN; PAIRED HELICAL FILAMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TAUOPATHY; UBIQUITINATION; ANIMAL; C57BL MOUSE; DEFICIENCY; GENETICS; HIPPOCAMPUS; KNOCKOUT MOUSE; METABOLISM; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; ULTRASTRUCTURE;

ANIMALS; AXONS; CALPAIN; CYCLIN-DEPENDENT KINASE 5; HIPPOCAMPUS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; MYRISTIC ACID; NERVE DEGENERATION; NEUROGENESIS; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RECEPTORS, SIGMA; TAU PROTEINS;

EID: 84930225723     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1422001112     Document Type: Article

References (59)

1. Lesnick TG, et al. (2007) A genomic pathway approach to a complex disease: Axon guidance and Parkinson disease. PLoS Genet 3(6):e98.
2. Lin L, Lesnick TG, Maraganore DM, Isacson O (2009) Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics. Trends Neurosci 32(3):142-149.
3. Kubo T, Yamaguchi A, Iwata N, Yamashita T (2008) The therapeutic effects of Rho- ROCK inhibitors on CNS disorders. Ther Clin Risk Manag 4(3):605-615.
4. Hahn CM, et al. (2005) Role of cyclin-dependent kinase 5 and its activator P35 in local axon and growth cone stabilization. Neuroscience 134(2):449-465.
5. Del Río JA, et al. (2004) MAP1B is required for Netrin 1 signaling in neuronal migration and axonal guidance. Curr Biol 14(10):840-850.
6. Shukla V, Skuntz S, Pant HC (2012) Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch Med Res 43(8):655-662.
7. Dhavan R, Tsai LH (2001) A decade of CDK5. Nat Rev Mol Cell Biol 2(10):749-759.
8. Hisanaga S, Saito T (2003) The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. Neurosignals 12(4-5):221-229.
9. Chae T, et al. (1997) Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18(1):29-42.
10. Cruz JC, Tsai L-H (2004) A Jekyll and Hyde kinase: Roles for Cdk5 in brain development and disease. Curr Opin Neurobiol 14(3):390-394.
11. Ohshima T, et al. (1996) Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 93(20):11173-11178.
12. Shukla V, et al. (2013) A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J 27(1):174-186.
13. Bian F, et al. (2002) Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J Comp Neurol 446(3):257-266.
14. Patrick GN, et al. (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402(6762):615-622.
15. Su SC, Tsai L-H (2011) Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol 27:465-491.
16. Zhu Y-S, Saito T, Asada A, Maekawa S, Hisanaga S (2005) Activation of latent cyclin-dependent kinase 5 (Cdk5)-p35 complexes by membrane dissociation. J Neurochem 94(6):1535-1545.
17. Humbert S, Dhavan R, Tsai L (2000) p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J Cell Sci 113(pt 6):975-983.
18. Zhang L, Bonilla S, Zhang Y, Leung YF (2014) p35 promotes the differentiation of amacrine cell subtype in the zebrafish retina under the regulation of egr1. Dev Dyn 243(2):315-323.
19. Utreras E, et al. (2013) TGF-β1 sensitizes TRPV1 through Cdk5 signaling in odonto-blast-like cells. Mol Pain 9:24.
20. Utreras E, et al. (2009) Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35. J Biol Chem 284(4):2275-2284.
21. Lee MS, et al. (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405(6784):360-364.
22. Kusakawa G, et al. (2000) Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 275(22):17166-17172.
23. Nath R, et al. (2000) Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem Biophys Res Commun 274(1):16-21.
24. Asada A, et al. (2008) Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear localization of active cyclin-dependent kinase 5 complexes. J Neurochem 106(3):1325-1336.
25. Minegishi S, et al. (2010) Membrane association facilitates degradation and cleavage of the cyclin-dependent kinase 5 activators p35 and p39. Biochemistry 49(26):5482-5493.
26. Hayashi T, Su T-P (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131(3):596-610.
27. Mori T, Hayashi T, Hayashi E, Su T-P (2013) Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS ONE 8(10):e76941.
28. Tsai S-Y, et al. (2009) Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci USA 106(52):22468-22473.
29. Huang Y, et al. (2011) Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease. Curr Alzheimer Res 8(7): 765-770.
30. Fehér Á, et al. (2012) Association between a variant of the sigma-1 receptor gene and Alzheimer's disease. Neurosci Lett 517(2):136-139.
31. Tsai S-YA, Pokrass MJ, Klauer NR, De Credico NE, Su T-P (2014) Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders. Expert Opin Ther Targets 18(12):1461-1476.
32. Lahmy V, et al. (2013) Blockade of Tau hyperphosphorylation and Aβ1-42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ1receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuro-sychopharmacology 8(9):1706-1723.
33. Palmer CP, Mahen R, Schnell E, Djamgoz MBA, Aydar E (2007) Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res 67(23): 1166-11175.
34. Su TP, London ED, Jaffe JH (1988) Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 240(4849):219-221.
35. Ortega-Roldan JL, Ossa F, Schnell JR (2013) Characterization of the human sigma-1 receptor chaperone domain structure and binding immunoglobulin protein (BiP) interactions. J Biol Chem 288(29):21448-21457.
36. Ramachandran S, et al. (2009) The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. Eur J Pharmacol 609(1-3):19-26.
37. Arif M, Kazim SF, Grundke-Iqbal I, Garruto RM, Iqbal K (2014) Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam. Proc Natl Acad Sci USA 111(3):1144-1149.
38. Louis JV, et al. (2011) Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci USA 108(17):6957-6962.
39. Plattner F, Angelo M, Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281(35):25457-25465.
40. Mandelkow E-M, Stamer K, Vogel R, Thies E, Mandelkow E (2003) Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24(8):1079-1085.
41. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow E-M (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156(6):1051-1063.
42. Gray E, et al. (2013) Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis. Mult Scler 19(2):153-161.
43. Sternberger NH, Sternberger LA, Ulrich J (1985) Aberrant neurofilament phosphorylation in Alzheimer disease. Proc Natl Acad Sci USA 82(12):4274-4276.
44. Pollanen MS, Bergeron C, Weyer L (1994) Characterization of a shared epitope in cortical Lewy body fibrils and Alzheimer paired helical filaments. Acta Neuropathol 88(1):1-6.
45. Mishina M, et al. (2008) Low density of sigma1 receptors in early Alzheimer's disease. Ann Nucl Med 22(3):151-156.
46. Maruszak A, et al. (2007) Sigma receptor type 1 gene variation in a group of Polish patients with Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 23(6):432-438.
47. Francardo V, et al. (2014) Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain 137(pt 7):1998-2014.
48. Mishina M, et al. (2005) Function of sigma1 receptors in Parkinson's disease. Acta Neurol Scand 112(2):103-107.
49. Luty AA, et al. (2010) Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol 68(5):639-649.
50. Al-Saif A, Al-Mohanna F, Bohlega S (2011) A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol 70(6):913-919.
51. Belzil VV, et al. (2013) Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. Eur J Hum Genet 21(2):237-239.
52. Schmitt F, Hussain G, Dupuis L, Loeffler J-P, Henriques A (2014) A plural role for lipids in motor neuron diseases: Energy, signaling and structure. Front Cell Neurosci 8:25.
53. Yadav RS, Tiwari NK (2014) Lipid integration in neurodegeneration: An overview of Alzheimer's disease. Mol Neurobiol 50(1):168-176.
54. Hayashi T, Hayashi E, Fujimoto M, Sprong H, Su T-P (2012) The lifetime of UDP-galactose:ceramide galactosyltransferase is controlled by a distinct endoplasmic reticulum-associated degradation (ERAD) regulated by sigma-1 receptor chaperones. J Biol Chem 287(51):43156-43169.
55. Tsai S-Y, Rothman RK, Su T-P (2012) Insights into the Sigma-1 receptor chaperone's cellular functions: a microarray report. Synapse 66(1):42-51.
56. Hallows JL, Chen K, DePinho RA, Vincent I (2003) Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci 23(33):10633-10644.
57. Zheng Y-L, et al. (2007) Cdk5 Modulation of mitogen-activated protein kinase signaling regulates neuronal survival. Mol Biol Cell 18(2):404-413.
58. Hyrskyluoto A, et al. (2013) Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NFκB pathway. Cell Death Dis 4:e646.
59. Hong WC, Amara SG (2010) Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding. J Biol Chem 285(42):32616-32626.